Drug Discovery Today 2014 v.19 №08

London, UK.: Elsevier. — 224 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Changing role of formulation in biologics drug development
Tom SaylorAn overview of FDA-approved new molecular entities: 1827–2013
Michael S. Kinch, Austin Haynesworth, Sarah L. Kinch and Denton HoyerHigh-throughput epitope binning of therapeutic monoclonal antibodies: why you need to bin the fridge
Benjamin D. Brooks, Adam R. Miles and Yasmina N. AbdicheRecombinant probiotics with antimicrobial peptides: a dual strategy to improve immune response in immunocompromised patients
Santi M. Mandal, Osmar N. Silva and Octavio L. FrancoAdenosine and inflammation: what’s new on the horizon?
Luca Antonioli, Balázs Csóka, Matteo Fornai, Rocchina Colucci, Endre Kókai, Corrado Blandizzi and
György HaskóActivity cliffs in drug discovery: Dr Jekyll or Mr Hyde?
Maykel Cruz-Monteagudo, José L. Medina-Franco, Yunierkis Pérez-Castillo, Orazio Nicolotti, M. Natália D.S. Cordeiro and Fernanda BorgesSearch strategies and evaluation in protein–protein docking: principles, advances and challenges
Sheng-You HuangMucus models to evaluate nanomedicines for diffusion
Anne-Claire Groo and Frederic LagarceA 21st-century approach to age–old problems: the ascension of biologics in clinical therapeutics
Michael J. Espiritu, Abby C. Collier and Jon-Paul BinghamConsidering a new paradigm for Alzheimer’s disease research
Gillian R. LangleySystems mapping of genes controlling chemotherapeutic drug efficiency for cancer stem cells
Weimiao Wu, Sisi Feng, Yaqun Wang, Ningtao Wang, Han Hao and Rongling WuExploratory toxicology as an integrated part of drug discovery. Part I: Why and how
Jorrit J. Hornberg, Morten Laursen, Nina Brenden, Mikael Persson, Annemette V. Thougaard, Dorthe B. Toft and Tomas MowExploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies
Jorrit J. Hornberg, Morten Laursen, Nina Brenden, Mikael Persson, Annemette V. Thougaard, Dorthe B. Toft and Tomas MowA potential role for GPR55 in the regulation of energy homeostasis
Anna C. Simcocks, Lannie O’Keefe, Kayte A. Jenkin, Michael L. Mathai, Deanne H. Hryciw and Andrew J. McAinchThemed section: Rheumatology/Mechanisms underlying inflammatort bone & joint disease
Guest Editor: Costantino PitzalisPathogenesis of rheumatoid arthritis: from systemic autoimmunity to localised joint disease
Costantino PitzalisNovel immunological targets in rheumatic diseases: clues from current therapies
Fulvio D’Acquisto, Lorenza Rattazzi, Giuseppa Piras and Maria Letteria GaluppoPeripheral and synovial mechanisms of humoral autoimmunity in rheumatoid arthritis
Elisa Corsiero, Costantino Pitzalis and Michele BombardieriResolution of inflammation: examples of peptidergic players and pathways
Tazeen J. Ahmed, Magdalena K. Kaneva, Costantino Pitzalis, Dianne Cooper and Mauro PerrettiCellular and molecular mechanisms of cartilage damage and repair
Joanna C. Sherwood, Jessica Bertrand, Suzanne E. Eldridge and Francesco Dell’AccioCellular and molecular mechanisms of bone damage and repair in infl ammatory arthritis
Catherine Swales and Afsie SabokbarResolution of inflammation: targeting GPCRs that interact with lipids and peptides
Jenna L. Cash, Lucy V. Norling and Mauro PerrettiThemed section: Autoimmunity
Guest Editor: Esteban Masuda and Donald G. PayanTargeting autoimmunity: strategies and tactics
Esteban S. Masuda and Donald G. PayanPI3K inhibitors as potential therapeutics for autoimmune disease
Jennifer Ball, Sophie Archer and Stephen WardBruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Jennifer A. Whang and Betty Y. ChangInhibiting ROR t/Th17 axis for autoimmune disorders
Fujio Isono, Saori Fujita-Sato and Shuichiro ItoTargeting IL-34 in chronic inflammation
Emma L. Masteller and Brian R. WongProtein kinase C inhibitors for immune disorders
Amnon Altman and Kok-Fai KongHistamine H4 receptor antagonists for the treatment of inflammatory disorders
Wai L. LiuThemed section: Pulmonary Disease
Guest Editor: R James WhiteDrug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed
R. James White, Katie L. Lannan and Richard P. PhippsThrombosis, platelets, microparticles and PAH: more than a clot
Katie L. Lannan, Richard P. Phipps and R. James WhiteEndpoints in PAH clinical trials in the era of combination therapy: How do we decide whether something is working without going bankrupt?
Neil McGlinchey and Andrew J. PeacockRescuing the BMPR2 signaling axis in pulmonary arterial hypertension
James West, Eric Austin, Joshua P. Fessel, James Loyd and Rizwan HamidAssessment of right ventricular responses to therapy in pulmonary hypertension
Onno A. Spruijt, Harm-Jan Bogaard and Anton Vonk-NoordegraafInflammation in pulmonary hypertension: what we know and what we could logically and safely target first
Sylvia Cohen-Kaminsky, Aurélie Hautefort, Laura Price, Marc Humbert and Frédéric PerrosHow do we measure pathology in PAH (lung and RV) and what does it tell us about the disease
Rubin M. Tuder